Generation Bio Co. (GBIO) Stock

About Generation Bio Co.

Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.

Generation Bio Co. is headquartered in US.

Generation Bio Co. (GBIO) stock trades at $5.34 with a market capitalization of $35.98M. The stock is valued at a price-to-earnings (P/E) ratio of -0.87, price-to-book of 0.71, price-to-sales of 3.25. Over the past 52 weeks the stock has ranged between $3.00 and $7.52, and currently trades 29.0% below its 52-week high.

On profitability, Generation Bio Co. generates a return on equity (ROE) of -69.52%, return on capital employed of -60.50%, an operating margin of -550.62%, a net profit margin of -372.18%.

Official website: generationbio.com